The psychological impact of disclosing amyloid status to Japanese elderly: a preliminary study on asymptomatic patients with subjective cognitive decline

Abstract

In Japan, 4.6 million people are living with dementia and the number is expected to rise to 7 million by 2025. Amyloid-β (Aβ) positron emission tomography (PET) is used for cognitively normal Japanese people with or without subjective cognitive decline (SCD) for the purpose of clinical trials or diagnosis. Nevertheless, no empirical studies have been conducted on the safety of disclosing amyloid status to such populations. We conducted amyloid PET imaging on 42 participants (Aβ positive (n = 10) and negative (n = 32)). State anxiety and depression were measured at pre- and post-disclosure, and test-related distress at post-disclosure. Mean state anxiety and depression scores were below the cut-off through pre- and post-disclosure in the Aβ positive and negative groups. State anxiety and depression did not change over time and were not different between groups. Mean test-related distress scores were within normal limits at post-disclosure in both groups. No significant difference was found between groups. Disclosing Aβ positive results did not cause greater mood disturbance than negative results in a short period of time. The short-term psychological safety of disclosing Aβ PET results to asymptomatic Japanese adults with SCD was indicated.

Disclosure of Amyloid Status for Risk of Alzheimer Disease to Cognitively Normal Research Participants With Subjective Cognitive Decline: A Longitudinal Study

“…These findings are consistent with previous studies that focused on cognitively normal participants who were not distinguished from each other based on the presence or absence of SCD, 19,20 a study on patients with mild cognitive impairment (MCI) and AD, 41 and our preliminary study. 21 Individual participant-level analysis (Table 2) identified 5 extremes on the high end of the distribution: 1 in the STAI (state), 2 in the BDI-II, and 2 in the IES-R. However, the scores of the remaining 2 other measurements of each participant did not change or decreased.…”

Use of day services improved cognitive function in patients with Alzheimer's disease

“…1,2 The Japanese government estimates that 7 million Japanese people will be diagnosed with dementia by 2025. 2,3 Alzheimer's disease (AD) is not only the most common cognitive disease, but it also affects a rapidly increasing number of patients because advanced age is a major risk factor for the condition. 4,5 Although the essential aetiology of AD is unclear, cholinesterase inhibitors (e.g.…”

Japanese Old Stories Cognitive Scale: a screening test to detect cognitive disease and prompt visiting a memory clinic

“…This has brought an increase in biomedical and other problems among the elderly population, including dementia and the need for long‐term nursing care . The Japanese Ministry of Health, Labour and Welfare estimate that 7 million Japanese people will be diagnosed with dementia in 2025 . The three most common cognitive diseases in Japan are Alzheimer's disease (AD), vascular dementia (VaD), and dementia with Lewy bodies (DLB) .…”

“…1,2 The Japanese Ministry of Health, Labour and Welfare estimate that 7 million Japanese people will be diagnosed with dementia in 2025. 2,3 The three most common cognitive diseases in Japan are Alzheimer's disease (AD), vascular dementia (VaD), and dementia with Lewy bodies (DLB). 4 Of these, AD is not only the most common, it is affecting a rapidly increasing number of patients because advanced age is a major risk factor.…”